{"id":"glybuthiazol","rwe":[],"tags":[{"label":"glybuthiazol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"r. p. 2259","offLabel":[],"synonyms":["R. P. 2259","glybuthiazol","glybuthiazole","glipasol","glypasol"],"timeline":[],"approvals":[],"brandName":"R. P. 2259","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"glybuthiazol","explanation":"Imagine your body's cells are like locks, and Glybuthiazol is a key that fits into one of those locks. When it binds to the lock, it can either turn it on or off, depending on the type of lock and the key's shape. This interaction can help regulate various bodily functions, but more research is needed to understand exactly how Glybuthiazol works.","oneSentence":"Glybuthiazol is thought to work by interacting with a specific molecular target, although this target is currently unknown.","technicalDetail":"Glybuthiazol is a small molecule that likely binds to a specific protein or receptor, altering its activity and leading to downstream effects on cellular function."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3268","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GLYBUTHIAZOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T13:49:02.836720","biosimilars":[],"competitors":[],"genericName":"glybuthiazol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"35421N8E8W","CHEBI":"CHEBI:135337","INN_ID":"708","UMLSCUI":"C2348868","ChEMBL_ID":"CHEMBL94087","KEGG_DRUG":"D02462","PUBCHEM_CID":"10811"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R. P. 2259, also known as Glybuthiazol, is a small molecule drug in the glybuthiazol class. Unfortunately, there is limited information available on this compound, including its target, approved indications, and commercial status. As a result, it is difficult to provide a comprehensive summary of its use and safety profile. Further research is needed to determine the potential benefits and risks of Glybuthiazol. Currently, there is no information available on its half-life, bioavailability, or generic manufacturers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}